State-of-the-art genomics approaches in toxicology.
Genomics may be an effective tool in decreasing the lengthy drug development process and reducing compound attrition. It can generate specific gene expression profiles induced by chemicals that can be linked to dose and response. Toxicogenomics can identify sensitive biomarkers of early deleterious effects, distinguish genotoxic from non-genotoxic carcinogens and can provide information on the mechanism of action. It can help bridge in vitro to in vivo findings and provide context for preclinical data and thus address human health risks. Issues and shortcomings that still need to be resolved or improved for efficient incorporation of genomics in drug development and environmental toxicology research include data analysis, data interpretation tools and accessible data repositories. In addition, implementation of toxicogenomics in early screening or drug discovery phases and effective use of this information by project teams remains a challenge.
Van Hummelen
Paul
P
MicroArray Facility, VIB, Herestraat 18, 3000 Leuven, Belgium. paulvh@eohsi.rutgers.edu
Sasaki
Jennifer
J
D000818:Animals; D015415:Biomarkers; D002273:Carcinogens; D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D020869:Gene Expression Profiling; D023281:Genomics / Q000379:methods / Q000639:trends*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods; D043922:Toxicogenetics / Q000639:trends; D014116:Toxicology / Q000379:methods / Q000639:trends*
D015415:Biomarkers; D002273:Carcinogens